NEW YORK, August 5, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Tyson Foods, Inc. (NYSE: TSN), Kraft Foods Group Inc. (NASDAQ: KRFT), Kellogg Company (NYSE: K), Colgate-Palmolive Company (NYSE: CL) and Bunge Ltd. (NYSE: BG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5465-100free.
--
Tyson Foods, Inc. Research Reports
On July 31, 2014, Tyson Foods, Inc. (Tyson) announced that its Board of Directors has declared a quarterly dividend of $0.075 per share on Class A common stock and $0.0675 per share on Class B common stock, at a meeting held on July 30, 2014. According to Tyson, the aforesaid dividend is payable on December 15, 2014, to shareholders of record at the close of business on December 1, 2014. Further, the recently announced dividend is unchanged from dividend announced in previous quarter. The full research reports on Tyson are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/TSN/report.pdf
--
Kraft Foods Group Inc. Research Reports
On July 30, 2014, Kraft Foods Group Inc. (Kraft) released its Q2 FY 2014 and H1 FY 2014 financial results (period ended June 28, 2014). The Company reported Q2 FY 2014 net revenues of $4.75 billion, up 0.7% YoY. The Company stated that the Q2 FY 2014 revenues include a favorable impact of approx. 2.5 percentage points from shifting of Easter related shipments. According to Wall Street Journal, analysts polled by Thomson Reuters expected the Company to post Q2 FY 2014 EPS of $0.82 on revenue of $4.84 billion. The Company's Q2 FY 2014 net earnings came in at $482 million or $0.80 per diluted share, compared to net earnings of $829 million or $1.38 per diluted share in Q2 FY 2013. The Company reported H1 FY 2014 net revenues of $9.1 billion, down 1.3% YoY. The Company's H1 FY 2014 net earnings came in at $995 million or $1.65 per diluted share, compared to $1.3 billion or $2.14 per diluted share in H1 FY 2013. The full research reports on Kraft are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/KRFT/report.pdf
--
Kellogg Company Research Reports
On July 31, 2014, Kellogg Company (Kellogg) reported Q2 FY 2014 (period ended June 28, 2014) operating profit of $467 million, down 18.1% YoY due to costs associated with Project K, the company's four-year efficiency and effectiveness program, and lower sales. The Company reported Q2 FY 2014 net sales of $3.69 billion, down 0.8% YoY. According to Wall Street Journal, analysts polled by Thomson Reuters expected the Company to post Q2 FY 2014 EPS of $1.02 on revenue of $3.71 billion. The Company's Q2 FY 2014 net income attributable to Kellogg stood at $295 million or $0.82 per diluted share, compared to net income of $352 million or $0.96 per diluted share in Q2 FY 2013. The Company's H1 FY 2014 net sales declined 2.0% YoY to $7.4 billion. The Company's H1 FY 2014 net income attributable to Kellogg came in at $701 million or $1.94 per diluted share, compared to $663 million or $1.81 per diluted share in H1 FY 2013. The full research reports on Kellogg are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/K/report.pdf
--
Colgate-Palmolive Company Research Reports
On July 31, 2014, Colgate-Palmolive Company (Colgate) released its Q2 2014 and H1 2014 financial results. The Company reported Q2 2014 net sales of $4.35 billion, up 0.1% YoY, lagging the Zacks consensus revenue estimate of $4.40 billion. During the quarter, the Company's global unit volume grew 2.5%, pricing increased 1.5% and foreign exchange was negative 4.0%. The Company's Q2 2014 net income attributable to Colgate came in at $622 million or $0.67 diluted per share, compared to net income of $561 million or $0.60 per diluted share in Q2 2013. The Company's H1 2014 net sales improved 0.2% YoY to $8.7 billion. The Company's H1 2014 net income attributable to Colgate came in at $1.0 billion or $1.09 diluted per share, compared to $1.0 billion or $1.08 per diluted share in H1 2013. The full research reports on Colgate are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/CL/report.pdf
--
Bunge Ltd. Research Reports
On July 31, 2014, Bunge Ltd. (Bunge) reported Q2 2014 net sales of $16.79 billion, up 8.4% YoY. According to the Wall Street Journal, analysts polled by Thomson Reuters expected Q2 2014 EPS of $1.36 a share on revenue of $15.25 billion. The Company's Q2 2014 net income available to Bunge common shareholders came in at $272 million or $1.81 per diluted share, compared to net income of $110 million or $0.75 per diluted share in Q2 2013. The Company's H1 2014 net sales declined 0.1% YoY to $30.3 billion. The Company's H1 2014 net income available to Bunge common shareholders came in at $245 million or $1.65 per diluted share, compared to net income of $280 million or $1.90 per diluted share in H1 2013. The full research reports on Bunge are available to download free of charge at:
http://www.analystsreview.com/Aug-05-2014/BG/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
